Novavax (NVAX)
(Delayed Data from NSDQ)
$4.67 USD
+0.34 (7.85%)
Updated May 1, 2024 04:00 PM ET
After-Market: $4.60 -0.07 (-1.50%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.67 USD
+0.34 (7.85%)
Updated May 1, 2024 04:00 PM ET
After-Market: $4.60 -0.07 (-1.50%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine
by Zacks Equity Research
Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.
FDA Approves Pfizer & Moderna's New COVID Booster Vaccines
by Kinjel Shah
Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.
Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant
by Zacks Equity Research
Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.
Stocks on the Mend: A Mean Reversion Duo
by Andrew Rocco
September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.
Novavax (NVAX) Stock Increases 9% in a Month: Here's Why
by Zacks Equity Research
This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.
Pfizer (PFE) & BioNTech Get CHMP Nod for Updated Covid-19 Jab
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech receive a positive recommendation from the CHMP for its Omicron XBB.1.5-adapted Covid-19 vaccine.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More
by Zacks Equity Research
Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.
Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.
The Zacks Analyst Blog Highlights Moderna, BioNTech, Novavax and Pfizer
by Zacks Equity Research
Moderna, BioNTech, Novavax and Pfizer are included in this Analyst Blog.
U.S. Govt to Urge Citizens to Get New COVID-19 Shots
by Zacks Equity Research
Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.
Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.
Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut
by Zacks Equity Research
Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.
Novavax (NVAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Novavax (NVAX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of 146.77% and 64.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More
by Kinjel Shah
Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.
4 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Sundeep Ganoria
Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.
Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment
by Zacks Equity Research
Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.
Fast-paced Momentum Stock Novavax (NVAX) Is Still Trading at a Bargain
by Zacks Equity Research
Novavax (NVAX) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%
by Zacks Equity Research
Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.
Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab
by Zacks Equity Research
Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.